TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Objective Overall Response (OOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cτ,ss of linagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for recurrent Acute Coronary Syndrom (ACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ischaemic stroke or systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Circulating Tumor Cells (CTCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of RDTs for anti-HCV antibodies detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of RDTs for anti-HCV antibodies detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modulation of levels of total haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modulation of levels of deoxygenated haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modulation of levels of oxygenated haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: First occurrence of cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HFS-Child score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HFS-PYC score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HFS-Parent score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood Lactate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Care Heart Failure Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intra operative maternal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: In-Hospital Cardiac Arrest
Endpoint domain: Mortality/survival
Primary endpoint: Global Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantitative eyelid laxity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain symptoms of endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlqc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Flamingo balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit and reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing broad jump test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handgrip test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit-ups test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bent arm hang test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty meter endurance shuttle run test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients dialysed or not dialysed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hospital Anxiety and Depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of total radioactivity excreted in urine and feces combined
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of skin pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fat excretion in ileostomy effluent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Side effects in the treatment group
Endpoint domain: Adverse events/effects
Primary endpoint: Genotype of M. Leprae strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diaphragmatic thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cerebral blood flow data change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: impact of occult CNS disease on outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Overall Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment of Cancer Therapy Kidney Symptom Index - 15 (FKSI-15) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absence of peri-procedural stroke/TIA, device embolization, cardiac or vascular perforation, any other device or procedure-related serious adverse event or death
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the proportion of intratumoral lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in weekly daily average steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration (minutes) of moderate to vigorous intensity physical activity (MVPA) per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Predictive Value of Sentinel Lymph Node Prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gluteus medius muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of inconclusive results
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum pain score recorded during colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients admitted alive after AED shock
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in EPIC subdomain score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative cervical anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum measured concentration of the analyte in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Internal Hernias
Endpoint domain: Adverse events/effects
Primary endpoint: CSF to Plasma Concentration Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to re-obtain baseline cardiovascular parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in total mean daily step count
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reductions in Smoking Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in Smokeless Tobacco Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion signal intensity on Photoacoustic Imaging (PAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin A equivalency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Natural Killer Cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transfer to ICU due to severe COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Noradrenalin Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under Curve (AUC) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum serum concentration (Cmax) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time at which maximum serum concentration (Tmax) of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Curve (AUC) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum serum concentration (Cmax) of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With at Least One Treatment Emergent Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Radiation Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (complete or partial remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number and percentage of red lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects with treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Rhinoconjunctivitis Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global diagnostic preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in 24-hr Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LogMAR Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between breath acetone and blood beta-hydroxybutyrate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Body Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat Free Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody titer to hepatitis A vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Participation in cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: degree of hepatic impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: steady state nevirapine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in estimated clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Fractional Flow Reserve (FFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptom development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change-from-Baseline in Pupil Diameter (mm) During Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Pain VAS Score Within 12 Hours Postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of plasma glucose values within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-year Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Grade of Posterior Vitreous Detachment (PVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Release of vitreomacular traction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in psychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxidized/reduced glutathione ratio (GSH/GSSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weaning failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With HBV DNA < 400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Corneal Staining Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFF-1 and TFF-3 levels in gingival crevicular fluid, saliva, and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of trigger points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of pressure pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mass (lean mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective Respond Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of at least secondary school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Completion of at least graduate level education
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ever-married status
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Employment or enrollment in further education
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of patients with normalized IGF1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) of Alvocidib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma
Endpoint domain: Mortality/survival
Primary endpoint: Objective Response Rate in a Cohort of Patients With Angiosarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normalization of ALT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: VLDL-triglyceride kinetics (appearance rate and oxidation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogen glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in macular drusen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in macular drusen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Tracheal pressure (Ptrach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diastolic Circumferential Strain Rate During Isovolumic Relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early Diastolic Mitral Annular Velocity (E-prime) Using Tissue Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of resting energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sitting Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of disease confirmed by medical record review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Influenza Vaccine Coverage (Percent) for New Fathers of Newborns
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Influenza Vaccine Coverage (Percent) for All Household Contacts of Newborns
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained Virologic Response 12 Weeks After End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of myocardial ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of a postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: probability of reoperations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Hemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximally tolerated dose of SU011248
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Flare Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of quantitative FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of quantitative FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative rate of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients completing 80% of the proposed regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 5-year Disease-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Viral load in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of immunologic activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extent of CD8+ cell antiviral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Out of pocket (OOP) costs for treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Comprehensive Score for financial Toxicity (COST)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Surgical Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Spatial extent of activation of the visual cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Consistency of desired incisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of irinotecan in advanced sarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injury Severity Scores (ISSs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abbreviated Injury Scores (AISs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health of Nations Outcome Scale (HONOS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of patients enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients that completed minimum intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in 8 isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in microbiota population diversity from stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in microbiota population abundance from stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathological complete remission rate (pCR rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medium-term respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: expression of miRNA-138
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes